{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-22-000029","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2022-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.120584+00:00","generated_at":"2026-06-27T11:10:00.066972+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Immunovant Q3 net loss widens to $41.4M; cash at $527M; clinical pause continues","bullets":["Net loss of $41.4M ($0.36 per share) for Dec 2021 quarter vs. $31.8M ($0.32) a year ago.","R&D expenses rose to $29.8M from $21.1M, driven by clinical study costs and manufacturing.","Cash and equivalents of $527.0M as of Dec 31, 2021; no revenue reported.","G&A expenses increased to $11.5M from $10.5M year-over-year, partly due to stock-based compensation.","Clinical trial activities remain paused due to previously announced voluntary hold."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-22-000029","json":"https://secwatch.observer/filing/0001764013-22-000029.json","markdown":"https://secwatch.observer/filing/0001764013-22-000029.md","text":"https://secwatch.observer/filing/0001764013-22-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000029/0001764013-22-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000029/imvt-20220204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T11:10:00.066972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}